IIL's Karkapatla plant in Hyderabad is set to become India's largest producer of Animal Health Formulations

Chandigarh, October 26, 2015: Indian Immunologicals Limited (IIL), a leading biologicals company in India projects a brighter outlook for the company with the addition of a new state-of-the-art facility at Karkapatla, Ranga Reddy District, Telangana. This unit at Phase III of Genome Valley, Karkapatla is IIL's 2nd manufacturing unit in Hyderabad. Spread across on an area of 47 acres area, the plant will significantly expand IIL's manufacturing capabilities. The new facility has been established to manufacture vaccines against infectious diseases of Humans & animal health formulations catering to domestic as well as international markets.



IIL had developed this facility considering the growing demand for the next 10 years for Human vaccines and Animal health formulations. Human vaccine facility has been established to meet all WHO pre-qualification standards. The first phase of human vaccine facility has the capacity to produce 8 million doses of human rabies vaccine. The animal health formulation facility is equipped to produce an estimated capacity of 300 million tablets, 100 million bolus, and 20 million vials of injectables. The plant is equipped with cutting-edge German technology and has fully automated systems consisting of automated granulation, compression lines which have the least possible human intervention. This will become India's largest facility for producing animal health formulations. The facility currently equipped to manufacture Rabies vaccine for humans and produces new animal health formulations for bovines, sheep and pets. The unit will provide direct employment to 150 and indirect employment to 300 people.



Commenting on this, Dr. K Anand Kumar - Deputy Managing Director, Indian Immunologicals Limited, said "The facility will strengthen IIL's position in the industry and will immensely increase our manufacturing capabilities. We are expecting this plant to play a key role in manufacturing top quality vaccines with the most recent German technology. We will strive to maintain our industry leadership in providing the vaccines in the most affordable prices without compromising on the quality."



With the new addition, IIL has 5 manufacturing facilities at various locations - OOTY – Anti rabies production unit; Rajkot Gujarat – Cattle feed Unit; Hyderabad, Gachibowli – Biologicals Unit; New Zealand – Overseas Serum manufacturing unit. IIL currently employs around 1300 people.



About Indian Immunologicals Limited (IIL)



Indian Immunologicals Limited headquartered in Hyderabad, India is the market leader in veterinary biologicals and third largest animal health and human health player in India. IIL was setup by National Dairy Development Board (NDDB) in 1982 and pursues its mission of "Biotechnology in healthcare made affordable and accessible" in both the animal and human health segments and in the process creates a vibrant biotechnology base for the country and a leadership position in the international arena. IIL is the largest producer of Foot and Mouth disease vaccine in the world and was the first company in India to launch the purified Vero cell rabies vaccine for humans (PVRV) and second globally. IIL has a strong R&D and has launched several animal and human vaccines in the Indian market at affordable prices. R&D at IIL, specializes in development of varied types of vaccines ranging from inactivated and live viral vaccines, polysaccharide conjugate vaccines, recombinant subunit vaccines, toxoid vaccines, bacterial vaccines and molecular vaccines. More details about the company can be viewed on www.indimmune.com.

Originally Source : Perfect Relations